The British healthcare giant said it will pair its Journey II and Legion total knee implants with the VeriSense technology, designed to help surgeons optimize limb position and implant placement.
"Our Journey II total knee system with VeriLast technology is already delivering improved knee motion, patient function and implant wear reduction," Smith & Nephew orthopedic reconstruction president Gaurav Agarwal said in prepared remarks. "By combining our innovations with VeraSense’s exacting component placement and soft-tissue balancing our surgeons can deliver even more benefits to patients."
OrthoSensor won 510(k) clearance from the FDA for the VeraSense platform last summer. The agreement with Smith & Nephew is its latest pact with a major ortho player, following deals already in place with Zimmer (NYSE:ZMH) and Stryker (NYSE:SYK).
Late last year the Sunrise, Fla.-based medical device company added $13 million to its Series B round, taking the total raise to $48 million.
"OrthoSensor has an aggressive growth agenda, maximizing the relationships we have with our current partner companies and adding new partners, product lines and international markets in the coming year," president & CEO Jay Pierce said at the time. "This additional investment and continued confidence from our investors provides increased resources to maintain the rapid growth of our Verasense product line, as well as fund additional R&D, marketing and sales initiatives."
"We are seeing promising improvements in clinical outcomes and patient satisfaction in a multi-center study tracking patients balanced with VeraSense. We are pleased to work with Smith & Nephew to enable more surgeons to better treat their patients with our technology and the Journey II and Legion total knee systems," Pierce added today.